A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood—and it can support the cells’ growth for further analysis.
The device, believed to be the first to pair these functions, uses the advanced electronics material graphene oxide. In clinics, such a device could one day help doctors diagnose cancers, give more accurate prognoses and test treatment options on cultured cells without subjecting patients to traditional biopsies.
“If we can get these technologies to work, it will advance new cancer drugs and revolutionize the treatment of cancer patients,” said Max Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center and co-author of a paper on the new device, published online this week in Nature Nanotechnology.
“Circulating tumor cells will play a significant role in the early diagnosis of cancer and to help us understand if treatments are working in our cancer patients by serving as a ‘liquid’ biopsy to assess treatment responses in real time,” said co-author Dr. Diane Simeone, the Lazar J. Greenfield Professor of Surgery at the U-M Medical School and director of the Translational Oncology Program.
“Studies of circulating tumor cells will also help us understand the basic biologic mechanisms by which cancer cells metastasize or spread to distant organs—the major cause of death in cancer patients.”
Yet these cells aren’t living up to their promise in medicine because they are so difficult to separate from a blood sample, the researchers say. In the blood of early-stage cancer patients, they account for less than one in every billion cells, so catching them is tougher than finding the proverbial needle in a haystack.
“I can burn the haystack or use a huge magnet,” said Sunitha Nagrath, an assistant professor of chemical engineering, who led the research. “When it comes to circulating tumor cells, they almost look like—feel like—any other blood cell.”
On their microfluidic chip, Nagrath’s team grew dense forests of molecular chains, each equipped with an antibody to grab onto cancer cells.
Even after the cells are caught, it’s still hard to run a robust analysis on just a handful of them, the researchers say. That’s why this demonstration of highly sensitive tumor cell capture, combined with the ability to grow the cells in the same device, is so promising.
Hyeun Joong Yoon, a postdoctoral researcher in the Nagrath lab with a background in electrical engineering, was instrumental in making the microfluidic chip. He started with a silicon base and added a grid of nearly 60,000 flat gold shapes, like four-petaled flowers, each no wider than a strand of hair.
The gold flowers naturally attracted a relatively new material called graphene oxide. These sheets of carbon and oxygen, just a few atoms thick, layered themselves over the gold. This layered formation allowed the team to grow the tumor-cell-catching molecular chains so densely.
“It’s almost like each graphene has many nano-arms to capture cells,” Nagrath said.
To test the device, the team ran one-milliliter samples of blood through the chip’s thin chamber. Even when they had added just three-to-five cancer cells to the 5-10 billion blood cells, the chip was able to capture all of the cells in the sample half the time, with an average of 73 percent over 10 trials.
“That’s the highest anybody has shown in the literature for spiking such a low number of cells,” Nagrath said.
The Latest on: Liquid biopsy
- Liver cancer pipeline: 6 latest reportson October 14, 2019 at 6:05 am
Healio Gastroenterology and Liver Disease presents the following reports on the latest pipeline updates in liver cancer, including a T-cell therapy, two trials for second-line therapies, a combination ...
- New Testing for Dog Owners to Determine Early Stages of Canceron October 11, 2019 at 11:14 am
A newly approved liquid biopsy testing can now determine early stages of cancer in dogs with minimal cost and non-invasive procedure to save millions of lives and provide pet owners with better ...
- Grail Stays at Forefront of Liquid Biopsy Conversation with New Resultson October 10, 2019 at 11:45 am
The Menlo Park, CA-based company announced data validating the performance of its investigational multi-cancer early detection blood test for the first time in an independent cohort of participants.
- Pune company offers free liquid biopsy test for cancer patientson October 10, 2019 at 8:44 am
Picture for representational purpose only. The test does not need any special preparation like fasting or stopping any medicine. Patients can avail the free testing by booking the test online ...
- Analysis on the World Market for Liquid Biopsy with Emphasis on Cancer, 2017-2019 & 2023 - ResearchAndMarkets.comon October 10, 2019 at 8:13 am
The "Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering. Report Scope The scope of the report includes liquid biopsy technologies ...
- Novel approach based on InVision® liquid biopsy platform predicts response to immune checkpoint inhibitorson October 8, 2019 at 5:35 pm
Novel approach based on InVision ® liquid biopsy platform predicts response to immune checkpoint inhibitors Research Triangle Park, NC, USA and Cambridge, UK, October 8, 2019 -- Inivata, a leader in ...
- Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in Septemberon October 4, 2019 at 4:34 pm
Thanks to a handful of initial public offerings (IPOs) in the last year, individual investors can now own liquid biopsy stocks. Thanks to awful performance last month, most of them are trading at ...
- Liquid biopsy Market 2019 Intelligence Report for Comprehensive Information 2026on October 4, 2019 at 12:02 am
Oct 04, 2019 (The Expresswire) -- The study report on the Liquid biopsy Market has assessed the historical and current performance of this market, especially highlighting the key trends and growth ...
- Co-Diagnostics to Present Technology Applications at 4th ACTC Liquid Biopsy Conference in Corfu, Greeceon October 3, 2019 at 3:33 am
Liquid biopsy refers to an array of diagnostic tools that analyze blood samples—as opposed to tissue—to identify genetic mutations from “circulating tumor” DNA, or ctDNA, which indicate the presence ...
- Liquid biopsy: one cell at a timeon October 2, 2019 at 2:34 am
As an alternative target to surgically resected tissue specimens, liquid biopsy has gained much attention over the past decade. Of the various circulating biomarkers, circulating tumor cells (CTCs) ...
via Google News and Bing News